Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
MDxHealth Launches ConfirmMDx for Prostate Cancer
Volgen
* Reuters is not responsible for the content in this press release. Tue May 15, 2012 2:00am EDT MDxHealth Launches ConfirmMDx™ for Prostate Cancer First epigenetic test to help identify men who may avoid repeat biopsies Regulatory News: MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced the launch of ConfirmMDx™ for Prostate Cancer, a novel test that helps urologists distinguish patients who have a true-negative prostate biopsy from those who may have occult cancer. Testing will be performed in MDxHealth’s state-of-the-art Irvine-based CLIA laboratory for physicians submitting prostate tissue samples directly or via its exclusive co-marketing partner PLUS Diagnostics. “As many as one in four men could be misdiagnosed due to limitations with current prostate biopsy procedures, commonly described as ‘sampling error’. As a consequence, the standard of care for men with persistently high-risk factors, but no evidence of prostate cancer in a biopsy, is limited to continued surveillance and repeat biopsies, often on prostate-cancer-free men. The ConfirmMDx for Prostate Cancer test detects epigenetic changes associated with the presence or absence of prostate cancer,” explained Prof Dr. Wim van Crienkinge, Chief Scientific Officer of MDxHealth. “The launch of ConfirmMDx for Prostate Cancer represents the culmination of extensive research and development efforts and demonstrates the commitment of the MDxHealth team to deliver on its new commercial strategy,” said Dr. Jan Groen, CEO of MDxHealth. MDxHealth is uniquely positioned with its portfolio of epigenetic assays to capitalize on the realization of true personalized medicine, improving patient care, while reducing healthcare costs.” About ConfirmMDx for Prostate Cancer Over 650,000 American men receive a negative prostate biopsy result each year; however approximately 25-35% of these results are false negative. Under the current standard of care, prostate biopsy procedures collect 10-12 needle biopsy cores on average, effectively sampling less than 1% of a man’s prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on prostate-cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or “halo” associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular “halo” around a cancer lesion can be present despite having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying men who may forego unnecessary repeat biopsies. Please visit MDxHealth and PLUS Diagnostics at the American Urology Association Annual Meeting, May 19-23 2012 in Atlanta, GA, booths #3831 and #3923. About MDxHealth MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. By applying patented DNA methylation platform and biomarkers, MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. For more information visit www.mdxhealth.com and follow us on Twitter at: www.twitter.com/mdxhealth. Dr. Jan Groen will present on MDxHealth at the 13th annual meeting BioEquity Europe that is taking place on May 15th-16th in Frankfurt, Germany. This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. MDxHealth Dr. Jan Groen, CEO US: +1 949 812 6979 BE: +32 4 364 20 70info@mdxhealth.com or Halsin Partners Mike Sinclair UK: +44 20 7318 2955 Cell: +44 7968 022075msinclair@halsin.com www.reuters.com/article/2012/05/15/id...
Nu officieel op de website! Press Release MDxHealth Launches ConfirmMDx™ for Prostate Cancer MDxHealth Launches ConfirmMDx™ for Prostate Cancer First epigenetic test to help identify men who may avoid repeat biopsies IRVINE, CA, and LIEGE, BELGIUM, May 15, 2012 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced the launch of ConfirmMDx™ for Prostate Cancer, a novel test that helps urologists distinguish patients who have a true-negative prostate biopsy from those who may have occult cancer. Testing will be performed in MDxHealth's state-of-the-art Irvine-based CLIA laboratory for physicians submitting prostate tissue samples directly or via its exclusive co-marketing partner PLUS Diagnostics. "As many as one in four men could be misdiagnosed due to limitations with current prostate biopsy procedures, commonly described as 'sampling error'. As a consequence, the standard of care for men with persistently high-risk factors, but no evidence of prostate cancer in a biopsy, is limited to continued surveillance and repeat biopsies, often on prostate-cancer-free men. The ConfirmMDx for Prostate Cancer test detects epigenetic changes associated with the presence or absence of prostate cancer," explained Prof Dr. Wim van Crienkinge, Chief Scientific Officer of MDxHealth. "The launch of ConfirmMDx for Prostate Cancer represents the culmination of extensive research and development efforts and demonstrates the commitment of the MDxHealth team to deliver on its new commercial strategy," said Dr. Jan Groen, CEO of MDxHealth. "MDxHealth is uniquely positioned with its portfolio of epigenetic assays to capitalize on the realization of true personalized medicine, improving patient care, while reducing healthcare costs." About ConfirmMDx for Prostate Cancer Over 650,000 American men receive a negative prostate biopsy result each year; however approximately 25-35% of these results are false negative. Under the current standard of care, prostate biopsy procedures collect 10-12 needle biopsy cores on average, effectively sampling less than 1% of a man's prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on prostate-cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular "halo" around a cancer lesion can be present despite having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying men who may forego unnecessary repeat biopsies. Please visit MDxHealth and PLUS Diagnostics at the American Urology Association Annual Meeting, May 19-23 2012 in Atlanta, GA, booths #3831 and #3923. About MDxHealth MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. By applying patented DNA methylation platform and biomarkers, MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. For more information visit www.mdxhealth.com and follow us on Twitter at: www.twitter.com/mdxhealth. Dr. Jan Groen will present on MDxHealth at the 13th annual meeting BioEquity Europe that is taking place on May 15th-16th in Frankfurt, Germany. Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70info@mdxhealth.comCLOAKING Mike Sinclair Halsin Partners UK: +44 20 7318 2955 Cell: +44 7968 022075msinclair@halsin.comCLOAKING This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. English version Version Française
Morgen slechte cijfers???? 'k Heb het vaker meegemaakt dat 1 dag voor de cijfers een goed bericht wordt verspreid om zo een koersdip vanwege de slechte cijfers zo veel mogelijk te voorkomen.
MDxHealth lanceert test voor prostaatkanker Arne Petimezas - 15 mei 2012, 12:40 Een test van MDxHealth moet helpen aantonen of er daadwerkelijk sprake is van prostaatkanker. Volgens MDxHealth wordt bij mogelijk een op de vier mannen de al dan niet aanwezigheid van prostaatkanker verkeerd gediagnosticeerd. Als gevolg van de diagnostische problemen moeten mannen met een hoge kans op prostaatkanker steeds een biopsie laten doen. De test ConfirmMDx moet nu vaststellen of bij een biopsie, een weefseltest, echt geen kanker aanwezig is of dat er wel degelijk sprake van sporen van kanker. De tests met het middel zullen worden uitgevoerd in MDxHealths laboratorium in Irvine in de Amerikaanse staat Californië. Door: ABM Financial News. Info@abmfn.nl Hoofdredactie: +31(0)20-737 17 42 Redactie: +31(0)20-262 29 78
boxer2 schreef op 15 mei 2012 13:39 :
Morgen slechte cijfers????
'k Heb het vaker meegemaakt dat 1 dag voor de cijfers een goed bericht wordt verspreid om zo een koersdip vanwege de slechte cijfers zo veel mogelijk te voorkomen.
Waarom denk je dat? Ik verwacht veel specifieke details over de cijfers. En zie geen reden waarom de cashburn ver onder de verwachting is. DoC.
Door de marketingdeal met plusdx heeft mdxhealth haar netwerk vergroot en extra events op de agenda gezet: May 19-23, 2012 MDxHealth To Present at American Urology Association Annual Meetingwww.aua2012.org June 7-9, 2012 MDxHealth To Present at 2012 Texas Urological Society Annual Meetingwww.texasurologist.org/
Press Release MDxHealth’s ConfirmMDxTM for Prostate Cancer Test Helps to Identify Men Able to Avoid Repeat Biopsies Multi-Center MATLOC Data Presented at AUA Annual Meeting IRVINE, CA, and LIEGE, BELGIUM, 23 May, 2012 - January 9, 2012 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDxTM for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy. In men suspected to have prostate cancer, the potential for false-negative biopsy results is well documented in the literature. Approximately twenty-five percent of men receiving a negative histopathology result, the gold standard for diagnosis, could be harboring occult cancer. Fear over this issue leads to additional physician visits, screening, and repeat biopsies, often on prostate-cancer-free men. MDxHealth’s ConfirmMDx test assesses the DNA methylation status of genes associated with prostate cancer. The test will help urologists differentiate patients with a true-negative biopsy from those who may have cancer undetected by prostate biopsy and histopathological review. The data from the MATLOC (Methylation Analysis To Locate Occult Cancer) study presented during the Late Breaking Science Forum yesterday at the American Urology Association (AUA) Annual meeting in Atlanta, USA, revealed that the ConfirmMDx for Prostate Cancer test is a powerful tool to aid urologists in addressing false-negative biopsy concerns. "With a high negative predictive value, exceeding that of standard microscopic histopathology review, the MATLOC study results demonstrate that the ConfirmMDx for Prostate Cancer test can help urologists confirm true-negative biopsy results, providing peace-of-mind and reducing unnecessary repeat biopsies,” explained principle investigator Dr. Grant Stewart from the Edinburgh Urological Cancer Group at the University of Edinburgh, who presented the data. “The test will also help urologists identify high-risk men who may have occult cancer, enabling more effective triage of these patients with a repeat biopsy and treatment as required." "These data confirm the high negative predictive value (NPV) and clinical utility of the ConfirmMDx for Prostate Cancer genes and DNA methylation technology previously reported in published studies. We believe the test fulfills an unmet medical need, complementing the current standard of care, and holds the potential to reduce unnecessary invasive procedures and the associated healthcare expenditures. Prostate biopsies pose significant risk of trauma and infection, at times requiring hospitalization. As a consequence, approximately one-third of men refuse to endure a repeat biopsy despite fear of a false- negative result, leaving these men at risk for disease progression. ConfirmMDx, a non- invasive assay performed on the residual prostate tissues from the previous negative biopsy, provides critical insights beyond histopathology to enable more informed patient management decisions," said Dr. Jan Groen, CEO of MDxHealth. "We are pleased to announce that ConfirmMDx for Prostate Cancer is now available to urologists directly through MDxHealth’s state-of-the-art CLIA laboratory, and via our co-marketing partner PLUS Diagnostics.” Study Details The multicenter MATLOC study involved 3 sites from the UK and Belgium, testing tissue from initial negative biopsies and comparing assay results to cancer detection in subsequent biopsies within 30 months revealing either cancer (cases) or negative results (controls). Individual prostate biopsies comprised 10 separate tissue cores on average. ConfirmMDx for Prostate Cancer was used to analyze the methylation status of a panel of validated biomarkers (GSTP1, APC and RASSF1) in 4,681 archived prostate biopsy cores from 483 men in a blinded fashion. Results demonstrated that the assay had a NPV of 90% Application of this assay to initial, negative prostate biopsies accurately identified over two- thirds of patients who had cancer detected on a subsequent prostate biopsy, while correctly confirming negative findings in approximately two-thirds of men who were cancer-free in a subsequent prostate biopsy. The high NPV of 90% indicates this assay could help avoid unnecessary repeat prostate biopsies. Approximately 60% of positive assay results were indicated by one methylated gene while the remaining 40% of cases displayed two or more methylated genes. Univariate analyses identified that the methylation panel was a significant predictor of prostate cancer diagnosis. These findings were confirmed with a multivariate logistic regression, correcting for PSA, age, digital rectal examination results prior to initial biopsy and histopathological findings of this biopsy. The study entitled “Clinical utility of a multiplexed epigenetic gene assay to detect cancer in histopathologically negative prostate biopsies: results of the multicenter MATLOC study”, was presented by Dr. Grant Stewart from the Edinburgh Urological Cancer Group at the University of Edinburgh, on Tuesday, May 22, 2012 during the late breaking science session. Abstracts from the conference are available online. Over 650,000 American men receive a negative prostate biopsy result each year; however approximately 25-35% of these results are false negative. Under the current standard of care, prostate biopsy procedures collect 10-12 needle biopsy cores on average, effectively sampling less than 1% of a man’s prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on prostate-cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or “halo” associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular “halo” around a cancer lesion can be present despite having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying men who may forego unnecessary repeat biopsies. About MDxHealth MDxHealth is a leading molecular diagnostics company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit www.mdxhealth.com and follow us on Twitter at: www.twitter.com/mdxhealth. Dr. Jan Groen will present on MDxHealth on June 19th at 9:30 at the 2012 BioInternational Convention that is taking place in Boston (June 18-21) For more information: Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70info@mdxhealth.comCLOAKING Mike Sinclair Halsin Partners UK: +44 20 7318 2955 Cell: +44 7968 022075msinclair@halsin.comCLOAKING
Armzalig koersverloop! Geduld is bijna op! Hoelang nog?
Binckie 123 schreef op 25 mei 2012 13:48 :
Armzalig koersverloop! Geduld is bijna op! Hoelang nog?
Denk dat ik komende week maar weer wat 10k biedblokken erin moet gaan zetten. Als we het algemene sentiment bekijken mogen we niet klagen maar een koersprong met al dit goed nieuws had ik ook wel verwacht! European valdidation is nu erg belangrijk! Gezien de strikte wetgeving in amerika zie ik daarom zeker goedkeuring binnen Europa! DoC.
Wanneer wordt die Europese goedkeuring verwacht?
Binckie 123 schreef op 29 mei 2012 00:55 :
Wanneer wordt die Europese goedkeuring verwacht?
Kan niet lang duren Binckie, pakweg een aantal maanden! Tevens mooie ijsbergbied op 1,47 en 1,50. Er lijkt weer wat te gaan gebeuren!
Debit or Credit schreef:
[quote alias=Binckie 123 id=6294835 date=201205290055]
Wanneer wordt die Europese goedkeuring verwacht?
[/quote]
Kan niet lang duren Binckie, pakweg een aantal maanden! Tevens mooie ijsbergbied op 1,47 en 1,50. Er lijkt weer wat te gaan gebeuren!
Waar zie je die ijsbergen. Ik kan ze niet ontdekken
Op 1,47 en 1,50. Je ziet dat er een paar 100 staan in jou boekje terwijl er in werkelijkheid tienduizenden/honderdduizenden staan.
Debit or Credit schreef op 1 juni 2012 11:52 :
Op 1,47 en 1,50. Je ziet dat er een paar 100 staan in jou boekje terwijl er in werkelijkheid tienduizenden/honderdduizenden staan.
Dat klopt niet, ik verkocht 10k. Merendeel (8488) is gegaan op 1,46. Als er ijsberg had gelegen had ik er 1,47 minimaal voor gehad.
harrysnel schreef op 1 juni 2012 11:56 :
[...]
Dat klopt niet, ik verkocht 10k. Merendeel (8488) is gegaan op 1,46. Als er ijsberg had gelegen had ik er 1,47 minimaal voor gehad.
Je had ook een limiet op 1,50 of 1,47 moeten plaatsen. De particuliere belegger heeft toen inderdaad jou stukken deels op 1,46 over genomen! Wat was je reden tot verkoop harry?
@DOC: Reden voor verkoop is algemeen beurssentiment. Vaak wat latere reactie van lokale aandelen bij daling, wil dit plukje weer oppikken op lager niveau. Overigens gezien dat Agendia 50mln heeft opgehaald? www.iex.nl/Nieuws/ANP_ANP-310512-107/... Agendia wilde aanvankelijk naar beurs maar ging niet door vanwege slecht beursklimaat. Eerder heb ik op dit forum al geplaatst dat MDX-Health veel bestuurders kent afkomstig van Agendia. Ander raakvlak: Agendia heeft ook lab in Irvine, California. Sluit daarom samengaan niet uit. Misschien een reverse take-over van MDX-Health waardoor Agendia alsnog op beurs komt; Agendia heeft nu iig de financiele middelen. nb speculatie mijnerzijds
harrysnel schreef op 1 juni 2012 12:18 :
@DOC: Reden voor verkoop is algemeen beurssentiment. Vaak wat latere reactie van lokale aandelen bij daling, wil dit plukje weer oppikken op lager niveau.
Overigens gezien dat Agendia 50mln heeft opgehaald?
www.iex.nl/Nieuws/ANP_ANP-310512-107/... Agendia wilde aanvankelijk naar beurs maar ging niet door vanwege slecht beursklimaat. Eerder heb ik op dit forum al geplaatst dat MDX-Health veel bestuurders kent afkomstig van Agendia. Ander raakvlak: Agendia heeft ook lab in Irvine, California. Sluit daarom samengaan niet uit. Misschien een reverse take-over van MDX-Health waardoor Agendia alsnog op beurs komt; Agendia heeft nu iig de financiele middelen.
nb speculatie mijnerzijds
Super post Harry! Zelf ben ik groot particulier belegger en investeer nu 8 maanden in mdxh, zelf een belang van ruim 200.000 aandelen in die tijd opgebouwd met een kleine verkoop van 18.500 aandelen kendrion a 18,80. Ik sluit niet uit dat Mdx ook overgenomen kan worden. Ik zie je graag terug volgens mij is je kennis zeker de moeite waard om te delen. Mvg, DoC.
Laatste 1,60 2.000 12:28:59 Verschil 0,13 8,84%
Forum MDX is jammer genoeg niet zo actief maar kan natuurlijk veranderen. Dank voor de waardering:). Lees iig graag andere meningen over aandelen waar mijn interesse ligt. Juist lokale aandelen zijn m.i. de moeite waard, onbekend maakt soms onbemind en dan liggen er misschien kansen..
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee